Therapy Directory

Venetoclax clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Venetoclax as a study intervention. Browse Venetoclax recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

465

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Acute Myeloid Leukemia
Interventions: Decitabine, Venetoclax; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia, Lymphoma
Interventions: Capivasertib, Venetoclax, Rituximab, Blinatumomab, Nelarabine, mini-hyperCVD; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Lymphocytic Leukemia (CLL)
Interventions: Obinutuzumab, Venetoclax, Fludarabine, Cyclophosphamide, Rituximab, Bendamustine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Aurora, Colorado • Bethesda, Maryland • Knoxville, Tennessee + 1 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions: Decitabine, Venetoclax, FHD-286; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Peripheral blood draw, Bone marrow aspirate, Buccal swab; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Decitabine, Venetoclax; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Azacitidine (AZC), Venetoclax; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Uproleselan, Venetoclax; Drug
Lead sponsor: Brian Jonas; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Relapsed and Refractory Multiple Myeloma
Interventions: Selinexor, Venetoclax, Dexamethasone; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 3
States / cities: Coral Gables, Florida • Deerfield Beach, Florida • Miami, Florida

Conditions: Lymphoma, Non-Hodgkin Lymphoma, NHL, Hematologic Malignancies, Lymphoid Malignancies
Interventions: Vysis LSI MYC Break Apart Rearrangement Probe Kit, Venetoclax, VIP152, Prednisone, PET, EKG, ECHO, CT neck chest, abdomen, and pelvis, MRI, Bone marrow aspiration/Biopsy; Device · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Pirtobrutinib, Venetoclax; Procedure · Drug
Lead sponsor: Kerry Rogers; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

About this Venetoclax clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Venetoclax as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Venetoclax.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Venetoclax clinical trials

Filter and sort this therapy

Live official records

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi

About this Venetoclax clinical trials directory page